Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dare Bioscience, Inc. (DARE)
USD2.07
+0.00 (+0.00%)
US NASDAQ Healthcare Biotechnology
Address
3655 Nobel Drive 92122
San Diego, CA, US
San Diego, CA, US
CEO
Sabrina Martucci Johnson
Website
darebioscience.com
IPO
2014-04-10
CIK 1401914 ISIN US23666P2002
Description
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.07
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
642.4K
Beta
1.02
Float Shares
9.37M
Free Float %
98.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.98% | -3.40% | +59.55% | +67.06% | +50.26% | +47.15% | -1.73% | -76.57% | -80.91% | -98.92% | -99.65% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
2.07
Low
12.00
+479.7%
Consensus
12.00
+479.7%
Median
12.00
+479.7%
High
12.00
+479.7%
DCF (Unlevered)
197.23
+9,428.2%
DCF (Levered)
197.21
+9,427.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
12.00
+479.7%
|
Quality scores
Altman Z-Score
-8.82
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+10,429.4% ★ Q1'26: +499.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-150.0% Q1'26: +58.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,415.8% Q1'26: -3,621.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,315.5% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1,215.6% Q1'26: +65.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-232.96× Q1'26: -0.13× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
766.0K
est: 5.00M (-84.7%)
|
—
est: 645.0K (-100.0%)
|
—
est: 1.67M (-100.0%)
|
10.00M
est: 10.00M (+0.0%)
|
2.81M
est: 2.84M (-1.1%)
|
9.8K
est: 1.08M (-99.1%)
|
1.03M
est: 754.5K (+36.5%)
|
271.5K
211.4K – 331.6K
-64.0% YoY
|
5.36M
4.17M – 6.55M
+1,875.0% YoY
|
41.84M
32.57M – 51.10M
+680.2% YoY
|
141.31M
110.01M – 172.62M
+237.8% YoY
|
240.20M
186.99M – 293.41M
+70.0% YoY
|
| EBITDA |
-36.81M
est: -1,000.0K (-3,580.7%)
|
-27.36M
est: -129.0K (-21,108.7%)
|
-39.04M
est: -333.3K (-11,612.6%)
|
-31.36M
est: -2.00M (-1,468.1%)
|
-30.70M
est: -1.70M (-1,702.0%)
|
-23.41M
est: -647.9K (-3,513.0%)
|
-11.40M
est: -452.7K (-2,418.4%)
|
-162.9K
-199.0K – -126.8K
+64.0% YoY
|
-3.22M
-3.93M – -2.50M
-1,875.0% YoY
|
-25.10M
-30.66M – -19.54M
-680.2% YoY
|
-84.79M
-103.57M – -66.01M
-237.8% YoY
|
-144.12M
-176.04M – -112.19M
-70.0% YoY
|
| EBIT |
-37.07M
est: -1,000.0K (-3,606.8%)
|
-27.40M
est: -129.0K (-21,142.2%)
|
-39.07M
est: -333.3K (-11,620.6%)
|
-31.39M
est: -2.00M (-1,469.3%)
|
-30.74M
est: -1.70M (-1,704.2%)
|
-23.45M
est: -647.9K (-3,519.5%)
|
-13.55M
est: -452.7K (-2,893.7%)
|
-162.9K
-199.0K – -126.8K
+64.0% YoY
|
-3.22M
-3.93M – -2.50M
-1,875.0% YoY
|
-25.10M
-30.66M – -19.54M
-680.2% YoY
|
-84.79M
-103.57M – -66.01M
-237.8% YoY
|
-144.12M
-176.04M – -112.19M
-70.0% YoY
|
| Net Income |
-39.31M
est: -1.42B (+97.2%)
|
-27.40M
est: -83.44M (+67.2%)
|
-38.70M
est: -59.75M (+35.2%)
|
-30.95M
est: -39.77M (+22.2%)
|
-30.16M
est: -102.17M (+70.5%)
|
-4.05M
est: -39.13M (+89.6%)
|
-13.40M
est: -186.69M (+92.8%)
|
-135.26M
-174.22M – -96.31M
+27.5% YoY
|
-65.95M
-84.95M – -46.96M
+51.2% YoY
|
-11.18M
-22.72M – 358.9K
+83.1% YoY
|
175.51M
124.97M – 226.05M
+1,670.0% YoY
|
365.55M
260.28M – 470.81M
+108.3% YoY
|
| SGA |
10.36M
est: 943.19M (-98.9%)
|
6.55M
est: 121.67M (-94.6%)
|
8.35M
est: 314.40M (-97.3%)
|
11.24M
est: 1.89B (-99.4%)
|
11.91M
est: 539.92M (-97.8%)
|
9.16M
est: 205.32M (-95.5%)
|
8.76M
est: 143.46M (-93.9%)
|
51.62M
40.19M – 63.06M
-64.0% YoY
|
1.02B
793.68M – 1.25B
+1,875.0% YoY
|
7.95B
6.19B – 9.72B
+680.2% YoY
|
26.87B
20.92B – 32.82B
+237.8% YoY
|
45.67B
35.55B – 55.79B
+70.0% YoY
|
| EPS |
-14.20
est: -166.80 (+91.5%)
|
-10.93
est: -9.82 (-11.3%)
|
-7.52
est: -7.03 (-6.9%)
|
-4.39
est: -3.80 (-15.5%)
|
-4.15
est: -0.91 (-354.1%)
|
-0.48
est: -0.35 (-37.1%)
|
-1.20
est: -1.67 (+28.1%)
|
-1.21
-1.56 – -0.86
+27.5% YoY
|
-0.59
-0.76 – -0.42
+51.2% YoY
|
-0.10
-0.20 – 0.00
+83.1% YoY
|
1.57
1.12 – 2.02
+1,670.0% YoY
|
3.27
2.33 – 4.21
+108.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
314.49M
OE per share TTM
20.70
Owner's Yield
763.73%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
31,827.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
1.09M
Insider transactions (90d)
0
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 15.9%3 | 30.34M | 15.90% | — | 30.34M | — | 30.34M | PN | Delaware | 2014-04-25 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 3.06M | 3.99% | — | 8.8K | 3.03M | 25.9K | IA | — | 2022-02-09 | ↗ |
| 3 | VANGUARD INDEX FUNDS - VANGUARD TOTAL STOCK MARKET INDEX FUND - 23-2671505 | 2.70M | 7.11% | — | — | — | — | IV | Delaware | 2021-02-08 | ↗ |
| 4 | Jonathan A. Flint | 1.66M | 3.50% | — | 1.66M | — | 1.66M | IN | — | 2021-02-12 | ↗ |
| 5 | Terrance G. McGuire | 1.66M | 3.50% | — | 1.66M | — | 1.66M | IN | — | 2021-02-12 | ↗ |
| 6 | Polaris Venture Management Co. III, L.L.C. | 1.19M | 2.50% | — | 1.19M | — | 1.19M | OO | — | 2021-02-12 | ↗ |
| 7 | Polaris Venture Partners III, L.P. | 1.14M | 2.40% | — | 1.14M | — | 1.14M | PN | — | 2021-02-12 | ↗ |
| 8 | Empery Asset Management, LP | 700.0K | 4.99% | — | 700.0K | — | — | PN | Delaware | 2019-01-15 | ↗ |
| 9 | Martin D. Hoe | 700.0K | 4.99% | — | 700.0K | — | — | IN | Delaware | 2019-01-15 | ↗ |
| 10 | Ryan M. Lane | 700.0K | 4.99% | — | 700.0K | — | — | IN | Delaware | 2019-01-15 | ↗ |
| 11 | CVI Investments, Inc. | 599.9K | 4.90% | — | 599.9K | — | 599.9K | CO | Cayman Islands | 2019-02-14 | ↗ |
| 12 | Heights Capital Management, Inc. | 599.9K | 4.90% | — | 599.9K | — | 599.9K | CO | Delaware | 2019-02-14 | ↗ |
| 13 | Hudson Bay Capital Management LP | 382.5K | 0.92% | — | 382.5K | — | — | PN | United States | 2021-02-09 | ↗ |
| 14 | Sander Gerber | 382.5K | 0.92% | — | 382.5K | — | — | IN | United States | 2021-02-09 | ↗ |
| 15 | VEF Management V, LLC | 301.5K | 4.99% | — | 301.5K | — | — | OO | Delaware | 2018-02-14 | ↗ |
| 16 | Venrock Associates V, L.P. | 301.5K | 4.99% | — | 301.5K | — | — | PN | Delaware | 2018-02-14 | ↗ |
| 17 | Venrock Entrepreneurs Fund V, L.P. | 301.5K | 4.99% | — | 301.5K | — | — | PN | Delaware | 2018-02-14 | ↗ |
| 18 | Venrock Management V, LLC | 301.5K | 4.99% | — | 301.5K | — | — | OO | Delaware | 2018-02-14 | ↗ |
| 19 | Venrock Partners Management V, LLC | 301.5K | 4.99% | — | 301.5K | — | — | OO | Delaware | 2018-02-14 | ↗ |
| 20 | Venrock Partners V, L.P. | 301.5K | 4.99% | — | 301.5K | — | — | PN | Delaware | 2018-02-14 | ↗ |
| 21 | CVF, LLC | 260.1K | 4.30% | 260.1K | — | 260.1K | — | OO | Delaware | 2018-02-09 | ↗ |
| 22 | Polaris Venture Partners Entrepreneurs’ Fund III, L.P. | 29.2K | 0.10% | — | 29.2K | — | 29.2K | PN | — | 2021-02-12 | ↗ |
| 23 | Polaris Venture Partners Founders’ Fund III, L.P. | 17.8K | 0.00% | — | 17.8K | — | 17.8K | PN | — | 2021-02-12 | ↗ |
| 24 | Abigail P. Johnson | — | 0.00% | — | — | — | — | IN | Delaware | 2016-09-12 | ↗ |
| 25 | Armen B. Shanafelt, Ph.D. | — | 0.00% | — | — | — | — | IN | Delaware | 2017-02-14 | ↗ |
| 26 | FMR LLC | — | 0.00% | — | — | — | — | HC | Delaware | 2016-09-12 | ↗ |
| 27 | LV Management Group, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2017-02-14 | ↗ |
| 28 | Lilly Ventures Fund I, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2017-02-14 | ↗ |
| 29 | S. Edward Torres | — | 0.00% | — | — | — | — | IN | Delaware | 2017-02-14 | ↗ |
| 30 | Steven E. Hall, Ph.D. | — | 0.00% | — | — | — | — | IN | Delaware | 2017-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
12
-15 vs prev Q
New positions
6
Closed positions
21
Increased
9
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 523.1K +128.2K (+32.5%) | 1.01M +180.2K (+21.7%) | 4.10% -0.351 pp | 0.00% +0.000 pp | USD2.75 -29.8% | 6 qtrs — |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 118.7K -4.7K (-3.8%) | 229.0K -30.1K (-11.6%) | 0.93% -0.461 pp | 0.00% +0.000 pp | USD2.97 -35.0% | 6 qtrs — |
| 3 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 70.0K +9.8K (+16.3%) | 135.1K +8.7K (+6.9%) | 0.55% -0.130 pp | 0.00% +0.000 pp | USD2.63 -26.6% | 5 qtrs — |
| 4 | TWO SIGMA INVESTMENTS, LP | 33.0K +33.0K (+100.0%) | 63.8K +63.8K (+100.0%) | 0.26% +0.259 pp | 0.00% +0.000 pp | USD1.93 +0.0% | 1 qtrs NEW |
| 5 | STATE STREET CORP | 23.5K +— (+0.0%) | 45.4K -4.0K (-8.1%) | 0.18% -0.081 pp | 0.00% +0.000 pp | USD3.24 -40.4% | 6 qtrs — |
| 6 | US BANCORP \DE\ | 20.9K +20.9K (+100.0%) | 40.4K +40.4K (+100.0%) | 0.16% +0.164 pp | 0.00% +0.000 pp | USD1.93 +0.0% | 1 qtrs NEW |
| 7 | UBS GROUP AG | 20.9K -1.7K (-7.5%) | 40.4K -7.1K (-15.0%) | 0.16% -0.091 pp | 0.00% +0.000 pp | USD2.78 -30.6% | 6 qtrs — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 19.3K -39.6K (-67.2%) | 37.2K -86.4K (-69.9%) | 0.15% -0.513 pp | 0.00% 0.000 pp | USD3.21 -39.9% | 6 qtrs — |
| 9 | VIRTU FINANCIAL LLC | 19.2K +1.5K (+8.2%) | 37.0K +— (+0.0%) | 0.15% -0.049 pp | 0.00% -0.001 pp | USD2.09 -7.7% | 2 qtrs — |
| 10 | TWO SIGMA ADVISERS, LP | 17.9K +17.9K (+100.0%) | 34.5K +34.5K (+100.0%) | 0.14% +0.140 pp | 0.00% +0.000 pp | USD1.93 +0.0% | 1 qtrs NEW |
| 11 | BLACKROCK, INC. | 17.0K +— (+0.0%) | 32.8K -2.9K (-8.1%) | 0.13% -0.058 pp | 0.00% +0.000 pp | USD3.24 -40.4% | 6 qtrs — |
| 12 | NORTHERN TRUST CORP | 15.4K +461.0 (+3.1%) | 29.8K -1.7K (-5.3%) | 0.12% -0.048 pp | 0.00% +0.000 pp | USD3.20 -39.7% | 6 qtrs — |
| 13 | RAYMOND JAMES FINANCIAL INC | 15.3K +— (+0.0%) | 29.6K -2.6K (-8.1%) | 0.12% -0.053 pp | 0.00% +0.000 pp | USD2.13 -9.4% | 3 qtrs — |
| 14 | LPL FINANCIAL LLC | 14.6K +14.6K (+100.0%) | 28.3K +28.3K (+100.0%) | 0.11% +0.115 pp | 0.00% +0.000 pp | USD1.93 +0.0% | 1 qtrs NEW |
| 15 | XTX TOPCO LTD | 11.0K +11.0K (+100.0%) | 21.2K +21.2K (+100.0%) | 0.09% +0.086 pp | 0.00% +0.001 pp | USD1.93 +0.0% | 1 qtrs NEW |
| 16 | OBJECTIVITY SQUARED, LLC | 10.9K +10.9K (+100.0%) | 21.1K +21.1K (+100.0%) | 0.09% +0.086 pp | 0.01% +0.012 pp | USD1.93 +0.0% | 1 qtrs NEW |
| 17 | JANE STREET GROUP, LLC | 10.6K +10.6K (+100.0%) | 20.4K +20.4K (+100.0%) | 0.08% +0.083 pp | 0.00% +0.000 pp | USD1.93 +0.0% | 1 qtrs NEW |
| 18 | PRICE T ROWE ASSOCIATES INC /MD/ | 10.2K +— (+0.0%) | 20.0K -2.0K (-9.1%) | 0.08% -0.035 pp | 0.00% +0.000 pp | USD3.24 -40.4% | 6 qtrs — |
| 19 | HRT FINANCIAL LP | 10.5K +10.5K (+100.0%) | 20.0K +20.0K (+100.0%) | 0.08% +0.082 pp | 0.00% +0.000 pp | USD1.93 +0.0% | 1 qtrs NEW |
| 20 | PARALLEL ADVISORS, LLC | 2.4K +2.4K (+100.0%) | 4.6K +4.6K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD1.93 +0.0% | 1 qtrs NEW |
| 21 | IFS ADVISORS, LLC | 950.00 +— (+0.0%) | 1.8K -162.0 (-8.1%) | 0.01% -0.003 pp | 0.00% 0.000 pp | USD0.34 +467.6% | 7 qtrs — |
| 22 | SBI SECURITIES CO., LTD. | 575.00 -1.0 (-0.2%) | 1.1K -100.0 (-8.3%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD3.12 -38.1% | 5 qtrs — |
| 23 | BANK OF AMERICA CORP /DE/ | 129.00 -2.0 (-1.5%) | 250.00 -25.0 (-9.1%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD2.85 -32.3% | 6 qtrs — |
| 24 | TOWER RESEARCH CAPITAL LLC (TRC) | 110.00 +110.0 (+100.0%) | 212.00 +212.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.93 +0.0% | 6 qtrs — |
| 25 | CALDWELL SUTTER CAPITAL, INC. | 17.00 +— (+0.0%) | 33.00 -3.0 (-8.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.29 +565.5% | 7 qtrs — |
| 26 | INSPIRE INVESTING, LLC | 12.00 +12.0 (+100.0%) | 23.00 +23.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.92 +0.5% | 1 qtrs NEW |
| 27 | CORNERSTONE PLANNING GROUP LLC | 2.00 -245.0 (-99.2%) | 4.00 -38.8K (-100.0%) | 0.00% -0.003 pp | 0.00% -0.006 pp | USD2.00 -3.5% | 7 qtrs — |
| 28 | CITIGROUP INC | — -2.0 (-100.0%) | — -4.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 29 | GLOBAL RETIREMENT PARTNERS, LLC | — -4.4K (-100.0%) | — -9.2K (-100.0%) | 0.00% -0.049 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 30 | MATHER GROUP, LLC. | — -84.0 (-100.0%) | — -176.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 31 | HIGHTOWER ADVISORS, LLC | — -11.7K (-100.0%) | — -24.6K (-100.0%) | 0.00% -0.132 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 91.5K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 351.8K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.5K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 4.0K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 298.85 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 691.4K | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.5K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 825.13 | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 333.15 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 36.71 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
253.4K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+253,400
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | JOHNSON SABRINA MARTUCCI | Director / Officer | A-Award | A | Common Stock Warrant (right to buy) | 21,600 | 4.00 | 86.4K | 21,600 | D | ↗ |
| 2026-01-30 | JOHNSON SABRINA MARTUCCI | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 172,000 | 1.81 | 311.3K | 172,000 | D | ↗ |
| 2026-01-30 | Haring-Layton MarDee | Officer | A-Award | A | Employee Stock Option (right to buy) | 49,000 | 1.81 | 88.7K | 49,000 | D | ↗ |
| 2025-09-04 | Haring-Layton MarDee | Officer | A-Award | A | Employee Stock Option (right to buy) | 57,000 | 2.13 | 121.4K | 57,000 | D | ↗ |
| 2025-07-09 | Steele Robin Joan | Director | A-Award | A | Stock Option (right to buy) | 4,500 | 2.44 | 11.0K | 4,500 | D | ↗ |
| 2025-07-09 | RASTETTER WILLIAM H | Director | A-Award | A | Stock Option (right to buy) | 4,500 | 2.44 | 11.0K | 4,500 | D | ↗ |
| 2025-07-09 | Matz Gregory W | Director | A-Award | A | Stock Option (right to buy) | 4,500 | 2.44 | 11.0K | 4,500 | D | ↗ |
| 2025-07-09 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 4,500 | 2.44 | 11.0K | 4,500 | D | ↗ |
| 2025-07-09 | Grossman Jessica D. | Director | A-Award | A | Stock Option (right to buy) | 4,500 | 2.44 | 11.0K | 4,500 | D | ↗ |
| 2025-01-28 | JOHNSON SABRINA MARTUCCI | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 107,000 | 3.27 | 349.9K | 107,000 | D | ↗ |
| 2025-01-28 | Haring-Layton MarDee | Officer | A-Award | A | Employee Stock Option (right to buy) | 38,000 | 3.27 | 124.3K | 38,000 | D | ↗ |
| 2024-06-05 | Steele Robin Joan | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.43 | 17.2K | 40,000 | — | ↗ |
| 2024-06-05 | RASTETTER WILLIAM H | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.43 | 17.2K | 40,000 | — | ↗ |
| 2024-06-05 | Matz Gregory W | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.43 | 17.2K | 40,000 | — | ↗ |
| 2024-06-05 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.43 | 17.2K | 40,000 | — | ↗ |
| 2024-06-05 | Grossman Jessica D. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.43 | 17.2K | 40,000 | — | ↗ |
| 2024-03-12 | JOHNSON SABRINA MARTUCCI | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 0.46 | 345.0K | 750,000 | — | ↗ |
| 2024-03-12 | Haring-Layton MarDee | Officer | A-Award | A | Employee Stock Option (right to buy) | 290,000 | 0.46 | 133.4K | 290,000 | — | ↗ |
| 2024-03-12 | Fair John A | Officer | A-Award | A | Employee Stock Option (right to buy) | 290,000 | 0.46 | 133.4K | 290,000 | — | ↗ |
| 2024-01-26 | Haring-Layton MarDee | Officer | — | D | Employee Stock Option (right to buy) | 25,000 | 1.03 | 25.8K | 0 | — | ↗ |
| 2023-06-21 | Steele Robin Joan | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.96 | 38.4K | 40,000 | — | ↗ |
| 2023-06-21 | RASTETTER WILLIAM H | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.96 | 38.4K | 40,000 | — | ↗ |
| 2023-06-21 | Ononye-Onyia Sophia Nnenna | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.96 | 38.4K | 40,000 | — | ↗ |
| 2023-06-21 | Matz Gregory W | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.96 | 38.4K | 40,000 | — | ↗ |
| 2023-06-21 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.96 | 38.4K | 40,000 | — | ↗ |
| 2023-06-21 | Grossman Jessica D. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.96 | 38.4K | 40,000 | — | ↗ |
| 2023-06-21 | Blanchard Cheryl R | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.96 | 38.4K | 40,000 | — | ↗ |
| 2023-01-24 | Walters-Hoffert Lisa | Officer | A-Award | A | Stock Option (right to buy) | 290,000 | 0.00 | — | 290,000 | — | ↗ |
| 2023-01-24 | JOHNSON SABRINA MARTUCCI | Officer | A-Award | A | Stock Option (right to buy) | 750,000 | 0.00 | — | 750,000 | — | ↗ |
| 2023-01-24 | Fair John A | Officer | A-Award | A | Stock Option (right to buy) | 290,000 | 0.00 | — | 290,000 | — | ↗ |
| 2022-06-23 | Steele Robin Joan | Director | A-Award | A | Stock Option (right to buy) | 38,000 | 0.00 | — | 38,000 | — | ↗ |
| 2022-06-23 | RASTETTER WILLIAM H | Director | A-Award | A | Stock Option (right to buy) | 38,000 | 0.00 | — | 38,000 | — | ↗ |
| 2022-06-23 | Ononye-Onyia Sophia Nnenna | Director | A-Award | A | Stock Option (right to buy) | 38,000 | 0.00 | — | 38,000 | — | ↗ |
| 2022-06-23 | Matz Gregory W | Director | A-Award | A | Stock Option (right to buy) | 38,000 | 0.00 | — | 38,000 | — | ↗ |
| 2022-06-23 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 38,000 | 1.31 | 49.8K | 38,000 | — | ↗ |
| 2022-06-23 | Grossman Jessica D. | Director | A-Award | A | Stock Option (right to buy) | 38,000 | 1.31 | 49.8K | 38,000 | — | ↗ |
| 2022-06-23 | Blanchard Cheryl R | Director | A-Award | A | Stock Option (right to buy) | 38,000 | 0.00 | — | 38,000 | — | ↗ |
| 2022-01-25 | Walters-Hoffert Lisa | Officer | A-Award | A | Stock Option (right to buy) | 185,000 | 1.59 | 294.2K | 185,000 | — | ↗ |
| 2022-01-25 | JOHNSON SABRINA MARTUCCI | Director / Officer | A-Award | A | Stock Option (right to buy) | 628,400 | 1.59 | 999.2K | 628,400 | — | ↗ |
| 2022-01-25 | Fair John A | Officer | A-Award | A | Stock Option (right to buy) | 185,000 | 1.59 | 294.2K | 185,000 | — | ↗ |
| 2021-06-24 | Steele Robin Joan | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.46 | 43.8K | 30,000 | — | ↗ |
| 2021-06-24 | RASTETTER WILLIAM H | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.46 | 43.8K | 30,000 | — | ↗ |
| 2021-06-24 | Matz Gregory W | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.46 | 43.8K | 30,000 | — | ↗ |
| 2021-06-24 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.46 | 43.8K | 30,000 | — | ↗ |
| 2021-06-24 | Grossman Jessica D. | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.46 | 43.8K | 30,000 | — | ↗ |
| 2021-06-24 | Blanchard Cheryl R | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.46 | 43.8K | 30,000 | — | ↗ |
| 2021-04-16 | Ononye-Onyia Sophia Nnenna | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-26 | Walters-Hoffert Lisa | Officer | A-Award | A | Stock Option (right to buy) | 168,000 | 2.59 | 435.1K | 168,000 | — | ↗ |
| 2021-01-26 | JOHNSON SABRINA MARTUCCI | Director / Officer | A-Award | A | Stock Option (right to buy) | 525,000 | 2.59 | 1.36M | 525,000 | — | ↗ |
| 2021-01-26 | Fair John A | Officer | A-Award | A | Stock Option (right to buy) | 168,000 | 2.59 | 435.1K | 168,000 | — | ↗ |
| 2020-06-25 | Steele Robin Joan | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 1.03 | 23.2K | 22,500 | — | ↗ |
| 2020-06-25 | RASTETTER WILLIAM H | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 1.03 | 23.2K | 22,500 | — | ↗ |
| 2020-06-25 | Matz Gregory W | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 1.03 | 23.2K | 22,500 | — | ↗ |
| 2020-06-25 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 1.03 | 23.2K | 22,500 | — | ↗ |
| 2020-06-25 | Grossman Jessica D. | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 1.03 | 23.2K | 22,500 | — | ↗ |
| 2020-06-25 | Blanchard Cheryl R | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 1.03 | 23.2K | 22,500 | — | ↗ |
| 2020-03-06 | Walters-Hoffert Lisa | Officer | A-Award | A | Employee Stock Option (right to buy) | 68,000 | 1.03 | 70.0K | 68,000 | — | ↗ |
| 2020-03-06 | JOHNSON SABRINA MARTUCCI | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 280,000 | 1.03 | 288.4K | 280,000 | — | ↗ |
| 2020-03-06 | Fair John A | Officer | — | D | Employee Stock Option (right to buy) | 75,000 | 0.76 | 57.0K | 0 | — | ↗ |
| 2019-11-20 | Blanchard Cheryl R | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 0.79 | 35.6K | 45,000 | — | ↗ |
| 2019-06-13 | Steele Robin Joan | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.90 | 20.3K | 22,500 | — | ↗ |
| 2019-06-13 | RASTETTER WILLIAM H | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.90 | 20.3K | 22,500 | — | ↗ |
| 2019-06-13 | Matz Gregory W | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.90 | 20.3K | 22,500 | — | ↗ |
| 2019-06-13 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.90 | 20.3K | 22,500 | — | ↗ |
| 2019-06-13 | HAWLEY ROGER | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.90 | 20.3K | 22,500 | — | ↗ |
| 2019-06-13 | Grossman Jessica D. | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 0.90 | 20.3K | 22,500 | — | ↗ |
| 2019-04-11 | HAWLEY ROGER | Director | P-Purchase | A | Common stock | 454,545 | 1.10 | 500.0K | 944,956 | — | ↗ |
| 2019-01-29 | Walters-Hoffert Lisa | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 0.76 | 56.9K | 75,000 | — | ↗ |
| 2019-01-29 | JOHNSON SABRINA MARTUCCI | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 195,000 | 0.76 | 148.0K | 195,000 | — | ↗ |
| 2018-09-13 | Matz Gregory W | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.03 | 46.4K | 45,000 | — | ↗ |
| 2018-09-07 | Walters-Hoffert Lisa | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 1.01 | 101.0K | 100,000 | — | ↗ |
| 2018-09-07 | JOHNSON SABRINA MARTUCCI | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 192,000 | 1.01 | 193.9K | 192,000 | — | ↗ |
| 2018-07-10 | Steele Robin Joan | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.35 | 60.8K | 45,000 | — | ↗ |
| 2018-07-10 | RASTETTER WILLIAM H | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.35 | 60.8K | 45,000 | — | ↗ |
| 2018-07-10 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.35 | 60.8K | 45,000 | — | ↗ |
| 2018-07-10 | HAWLEY ROGER | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.35 | 60.8K | 45,000 | — | ↗ |
| 2018-07-10 | Grossman Jessica D. | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 1.35 | 60.8K | 45,000 | — | ↗ |
| 2018-06-11 | HAWLEY ROGER | Director | P-Purchase | A | Common stock | 140,000 | 1.45 | 203.4K | 140,000 | — | ↗ |
| 2018-04-09 | Grossman Jessica D. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-19 | Walters-Hoffert Lisa | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-19 | Steele Robin Joan | Director | A-Award | A | Common Stock | 246,171 | 6.56 | 1.61M | 246,171 | — | ↗ |
| 2017-07-19 | RASTETTER WILLIAM H | Director | A-Award | A | Option to Purchase Common Stock | 2,000 | 6.56 | 13.1K | 2,000 | — | ↗ |
| 2017-07-19 | Kelley Susan L. | Director | A-Award | A | Option to Purchase Common Stock | 2,000 | 6.56 | 13.1K | 2,000 | — | ↗ |
| 2017-07-19 | JOHNSON SABRINA MARTUCCI | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-19 | HAWLEY ROGER | Director | A-Award | A | Option to Purchase Common Stock | 2,200 | 6.56 | 14.4K | 2,200 | — | ↗ |
| 2017-04-03 | FRIEDMAN PAUL A | Director | A-Award | A | Common Stock | 10,273 | 0.73 | 7.5K | 18,819 | — | ↗ |
| 2017-01-06 | GUIFFRE CHRISTOPHERD T | Director / Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 0.82 | 123.0K | 150,000 | — | ↗ |
| 2017-01-05 | Senderowicz Adrian | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 0.82 | 123.0K | 150,000 | — | ↗ |
| 2017-01-05 | ONeill James E | Officer | A-Award | A | Stock Option (right to buy) | 5,000 | 0.82 | 4.1K | 5,000 | — | ↗ |
| 2017-01-05 | Eliasof Scott | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 0.82 | 49.2K | 60,000 | — | ↗ |
| 2017-01-05 | Carvajal Alejandra | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.82 | 41.0K | 50,000 | — | ↗ |
| 2017-01-05 | BELOFF GREGG | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.82 | 41.0K | 50,000 | — | ↗ |
| 2017-01-03 | WALT DAVID R | Director | A-Award | A | Common Stock | 14,935 | 0.77 | 11.5K | 193,700 | — | ↗ |
| 2017-01-03 | RASTETTER WILLIAM H | Director | A-Award | A | Common Stock | 24,350 | 0.77 | 18.7K | 103,039 | — | ↗ |
| 2017-01-03 | Parkinson David Ross | Director | A-Award | A | Common Stock | 16,234 | 0.77 | 12.5K | 28,488 | — | ↗ |
| 2017-01-03 | MCKEE WILLIAM | Director | A-Award | A | Common Stock | 1,948 | 0.77 | 1.5K | 3,418 | — | ↗ |
| 2017-01-03 | FRIEDMAN PAUL A | Director | A-Award | A | Common Stock | 4,870 | 0.77 | 3.7K | 8,546 | — | ↗ |
| 2017-01-03 | Arbuckle Stuart A | Director | A-Award | A | Common Stock | 7,467 | 0.77 | 5.7K | 13,104 | — | ↗ |
| 2016-12-31 | GUIFFRE CHRISTOPHERD T | Director / Officer | A-Award | A | Common Stock | 5,733 | 0.60 | 3.4K | 12,489 | — | ↗ |
| 2016-10-25 | Eliasof Scott | Officer | — | D | Emplyee Stock Option (right to buy) | 9,953 | 3.34 | 33.2K | 0 | — | ↗ |
| 2016-10-03 | WALT DAVID R | Director | A-Award | A | Common Stock | 11,274 | 1.02 | 11.5K | 178,765 | — | ↗ |
| 2016-10-03 | RASTETTER WILLIAM H | Director | A-Award | A | Common Stock | 18,382 | 1.02 | 18.7K | 78,689 | — | ↗ |
| 2016-10-03 | Parkinson David Ross | Director | A-Award | A | Common Stock | 12,254 | 1.02 | 12.5K | 12,254 | — | ↗ |
| 2016-10-03 | MCKEE WILLIAM | Director | A-Award | A | Common Stock | 1,470 | 1.02 | 1.5K | 1,470 | — | ↗ |
| 2016-10-03 | FRIEDMAN PAUL A | Director | A-Award | A | Common Stock | 3,676 | 1.02 | 3.7K | 3,676 | — | ↗ |
| 2016-10-03 | Arbuckle Stuart A | Director | A-Award | A | Common Stock | 5,637 | 1.02 | 5.7K | 5,637 | — | ↗ |
| 2016-08-22 | Senderowicz Adrian | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 1.14 | 114.0K | 100,000 | — | ↗ |
| 2016-08-22 | ONeill James E | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 1.14 | 57.0K | 50,000 | — | ↗ |
| 2016-08-22 | Carvajal Alejandra | Officer | A-Award | A | Common Stock (right to buy) | 75,000 | 1.14 | 85.5K | 75,000 | — | ↗ |
| 2016-08-22 | BELOFF GREGG | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 1.14 | 85.5K | 75,000 | — | ↗ |
| 2016-06-30 | GUIFFRE CHRISTOPHERD T | Director / Officer | A-Award | A | Common Stock | 3,999 | 1.80 | 7.2K | 6,756 | — | ↗ |
| 2016-06-22 | WALT DAVID R | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.08 | 41.6K | 20,000 | — | ↗ |
| 2016-06-22 | RASTETTER WILLIAM H | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.08 | 41.6K | 20,000 | — | ↗ |
| 2016-06-22 | Parkinson David Ross | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.08 | 41.6K | 20,000 | — | ↗ |
| 2016-06-22 | MCKEE WILLIAM | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.08 | 41.6K | 20,000 | — | ↗ |
| 2016-06-22 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.08 | 41.6K | 20,000 | — | ↗ |
| 2016-06-22 | Hall Steven Edward | Director / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-06-22 | FRIEDMAN PAUL A | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.08 | 41.6K | 20,000 | — | ↗ |
| 2016-06-22 | Crane Alan L | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 20,000 | 2.08 | 41.6K | 20,000 | — | ↗ |
| 2016-06-22 | Arbuckle Stuart A | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.08 | 41.6K | 20,000 | — | ↗ |
| 2016-02-22 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 591 | 2.09 | 1.2K | 167,491 | — | ↗ |
| 2016-02-19 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 1,700 | 2.08 | 3.5K | 166,900 | — | ↗ |
| 2016-02-18 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.09 | 9.4K | 165,200 | — | ↗ |
| 2016-02-17 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,460 | 2.12 | 9.4K | 160,700 | — | ↗ |
| 2016-02-16 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.00 | 9.0K | 156,240 | — | ↗ |
| 2016-02-12 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,311 | 2.00 | 8.6K | 151,740 | — | ↗ |
| 2016-02-11 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,350 | 2.03 | 8.8K | 147,429 | — | ↗ |
| 2016-02-10 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.08 | 9.3K | 143,079 | — | ↗ |
| 2016-02-09 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.08 | 9.3K | 138,579 | — | ↗ |
| 2016-02-08 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.22 | 10.0K | 134,079 | — | ↗ |
| 2016-02-05 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.29 | 10.3K | 129,579 | — | ↗ |
| 2016-02-04 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,063 | 2.31 | 9.4K | 125,079 | — | ↗ |
| 2016-02-03 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,018 | 2.27 | 9.1K | 121,016 | — | ↗ |
| 2016-02-02 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,395 | 2.37 | 10.4K | 116,998 | — | ↗ |
| 2016-02-01 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.37 | 10.7K | 112,603 | — | ↗ |
| 2016-01-29 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 1,200 | 2.41 | 2.9K | 108,103 | — | ↗ |
| 2016-01-28 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.45 | 11.0K | 106,903 | — | ↗ |
| 2016-01-27 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.47 | 11.1K | 102,403 | — | ↗ |
| 2016-01-26 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,300 | 2.44 | 10.5K | 97,903 | — | ↗ |
| 2016-01-25 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.35 | 10.6K | 93,603 | — | ↗ |
| 2016-01-22 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.24 | 10.1K | 89,103 | — | ↗ |
| 2016-01-21 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.32 | 10.4K | 84,603 | — | ↗ |
| 2016-01-20 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.35 | 10.6K | 80,103 | — | ↗ |
| 2016-01-19 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,400 | 2.52 | 11.1K | 75,603 | — | ↗ |
| 2016-01-15 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,172 | 2.42 | 10.1K | 71,203 | — | ↗ |
| 2016-01-14 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,400 | 2.64 | 11.6K | 67,031 | — | ↗ |
| 2016-01-13 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,384 | 2.69 | 11.8K | 62,631 | — | ↗ |
| 2016-01-12 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,300 | 2.89 | 12.4K | 58,247 | — | ↗ |
| 2016-01-11 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,355 | 2.86 | 12.5K | 53,947 | — | ↗ |
| 2016-01-08 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 2.87 | 12.9K | 49,592 | — | ↗ |
| 2016-01-07 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,300 | 2.87 | 12.3K | 45,092 | — | ↗ |
| 2016-01-06 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 3.03 | 13.6K | 40,792 | — | ↗ |
| 2016-01-05 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,301 | 3.06 | 13.2K | 36,292 | — | ↗ |
| 2016-01-05 | Senderowicz Adrian | Officer | A-Award | A | Incentive Stock Option (right to buy) | 50,000 | 3.04 | 152.0K | 50,000 | — | ↗ |
| 2016-01-05 | ONeill James E | Officer | A-Award | A | Incentive Stock Option (right to buy) | 4,900 | 3.04 | 14.9K | 4,900 | — | ↗ |
| 2016-01-05 | GUIFFRE CHRISTOPHERD T | Director / Officer | A-Award | A | Incentive Stock Option (right to buy) | 137,000 | 3.04 | 416.5K | 137,000 | — | ↗ |
| 2016-01-05 | Carvajal Alejandra | Officer | A-Award | A | Incentive Stock Option (right to buy) | 45,000 | 3.04 | 136.8K | 45,000 | — | ↗ |
| 2016-01-04 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 4,500 | 3.01 | 13.5K | 31,991 | — | ↗ |
| 2015-12-31 | ONeill James E | Officer | A-Award | A | Common Stock | 1,098 | 2.38 | 2.6K | 2,098 | — | ↗ |
| 2015-12-31 | GUIFFRE CHRISTOPHERD T | Director / Officer | A-Award | A | Common Stock | 2,757 | 2.38 | 6.6K | 2,757 | — | ↗ |
| 2015-12-03 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 10,000 | 3.75 | 37.5K | 27,491 | — | ↗ |
| 2015-12-01 | Senderowicz Adrian | Officer | A-Award | A | Incentive Stock Option (right to buy) | 158,000 | 3.29 | 519.8K | 158,000 | — | ↗ |
| 2015-12-01 | Carvajal Alejandra | Officer | A-Award | A | Incentive Stock Option (right to buy) | 158,000 | 3.29 | 519.8K | 158,000 | — | ↗ |
| 2015-11-30 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 5,374 | 3.25 | 17.5K | 17,491 | — | ↗ |
| 2015-11-27 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 6,700 | 3.28 | 22.0K | 12,117 | — | ↗ |
| 2015-11-25 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 5,417 | 3.37 | 18.2K | 5,417 | — | ↗ |
| 2015-09-23 | WALT DAVID R | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 4.80 | 105.6K | 22,000 | — | ↗ |
| 2015-09-04 | Senderowicz Adrian | Officer | A-Award | A | Incentive Stock Option (right to buy) | 135,000 | 4.21 | 568.4K | 135,000 | — | ↗ |
| 2015-06-26 | TEPPER ROBERT I | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-06-26 | Sasisekharan Ram | Director / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-06-26 | RASTETTER WILLIAM H | Director | A-Award | A | Stock Option (Right to Buy) | 8,214 | 4.78 | 39.3K | 8,214 | — | ↗ |
| 2015-06-26 | Parkinson David Ross | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 4.78 | 52.6K | 11,000 | — | ↗ |
| 2015-06-26 | ONeill James E | Officer | — | D | Incentive Stock Option (right to buy) | 13,000 | 4.40 | 57.2K | 0 | — | ↗ |
| 2015-06-26 | MCKEE WILLIAM | Director | A-Award | A | Stock Option (Right to Buy) | 8,214 | 4.78 | 39.3K | 8,214 | — | ↗ |
| 2015-06-26 | Kelley Susan L. | Director | A-Award | A | Stock Option (Right to Buy) | 7,000 | 4.78 | 33.5K | 7,000 | — | ↗ |
| 2015-06-26 | Hall Steven Edward | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 11,000 | 4.78 | 52.6K | 11,000 | — | ↗ |
| 2015-06-26 | FRIEDMAN PAUL A | Director | A-Award | A | Stock Option (Right to Buy) | 8,214 | 4.78 | 39.3K | 8,214 | — | ↗ |
| 2015-06-26 | Crane Alan L | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 11,000 | 4.78 | 52.6K | 11,000 | — | ↗ |
| 2015-06-26 | Carvajal Alejandra | Officer | — | D | Stock Option (Right to Buy) | 55,000 | 4.40 | 242.0K | 0 | — | ↗ |
| 2015-06-26 | Arbuckle Stuart A | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 4.78 | 105.2K | 22,000 | — | ↗ |
| 2015-05-27 | BELOFF GREGG | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 5.89 | 530.1K | 90,000 | — | ↗ |
| 2015-04-07 | CVF, LLC | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 6.00 | 2.00M | 2,592,577 | — | ↗ |
| 2015-03-23 | GUIFFRE CHRISTOPHERD T | Director / Officer | A-Award | A | Stock Option (right to buy) | 407,520 | 9.84 | 4.01M | 407,520 | — | ↗ |
| 2015-02-05 | Roberts Karen Lynn | Officer | A-Award | A | Stock Option (right to buy) | 43,000 | 8.16 | 350.9K | 163,774 | — | ↗ |
| 2015-02-05 | Garmey Edward Graeme | Officer | A-Award | A | Stock Option (right to buy) | 43,000 | 8.16 | 350.9K | 166,586 | — | ↗ |
| 2015-02-05 | GUIFFRE CHRISTOPHERD T | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 8.16 | 612.0K | 317,457 | — | ↗ |
| 2014-10-29 | Parkinson David Ross | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.36 | 65.4K | 15,000 | — | ↗ |
| 2014-10-29 | GUIFFRE CHRISTOPHERD T | Officer | A-Award | A | Stock Option (Right to Buy) | 50,300 | 4.36 | 219.3K | 242,457 | — | ↗ |
| 2014-10-29 | FRIEDMAN PAUL A | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 4.36 | 436.0K | 113,786 | — | ↗ |
| 2014-10-29 | FETZER OLIVER | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-10-03 | Kelley Susan L. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.74 | 71.1K | 15,000 | — | ↗ |
| 2014-09-16 | Crane Alan L | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 16,000 | 3.92 | 62.7K | 16,000 | — | ↗ |
| 2014-07-17 | Roberts Karen Lynn | Officer | A-Award | A | Stock Option (right to buy) | 20,100 | 4.98 | 100.1K | 120,774 | — | ↗ |
| 2014-06-24 | Roberts Karen Lynn | Officer | A-Award | A | Stock Option (right to buy) | 38,200 | 5.73 | 218.9K | 100,674 | — | ↗ |
| 2014-06-24 | Garmey Edward Graeme | Officer | A-Award | A | Stock Option (right to buy) | 50,300 | 5.73 | 288.2K | 123,586 | — | ↗ |
| 2014-06-24 | GUIFFRE CHRISTOPHERD T | Officer | A-Award | A | Stock Option (right to buy) | 50,300 | 5.73 | 288.2K | 192,158 | — | ↗ |
| 2014-06-24 | FETZER OLIVER | Director / Officer | A-Award | A | Stock Option (right to buy) | 290,000 | 5.73 | 1.66M | 730,569 | — | ↗ |
| 2014-05-16 | FETZER OLIVER | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 30,000 | 3.34 | 100.2K | 102,215 | — | ↗ |
| 2014-04-15 | VENROCK ASSOCIATES V LP | 10% Owner | C-Conversion | D | Series B Convertible Preferred Stock | 1,868,955 | 0.00 | — | 0 | — | ↗ |
| 2014-04-15 | Rock Springs Capital Management LP | — | C-Conversion | D | 7% Convertible Promissory Notes | 0 | 5.43 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-5.9K
Shares Outstanding
9.52M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Sabrina Martucci Johnson President and Chief Executive Officer | 518.7K | — | — | 268.4K | — | 14.0K | 801.1K | 33.50% | ↗ |
| 2 | 2025 | MarDee Haring-Layton Chief Accounting Officer | 353.1K | — | — | 179.8K | — | 14.0K | 546.9K | 32.87% | ↗ |
| 3 | 2024 | Sabrina Martucci Johnson President and Chief Executive Officer | 495.0K | — | — | 257.0K | 132.6K | 13.8K | 898.4K | 28.60% | ↗ |
| 4 | 2024 | MarDee Haring-Layton Chief Accounting Officer | 330.0K | — | — | 103.4K | 66.0K | 13.8K | 513.2K | 20.15% | ↗ |
| 5 | 2024 | Lisa Walters-Hoffert Former Chief Financial Officer | 31.7K | — | — | — | 76.0K | 290.6K | 398.3K | 0.00% | ↗ |
| 6 | 2023 | Sabrina Martucci Johnson President and Chief Executive Officer | 495.0K | — | — | 713.9K | — | 13.2K | 1.22M | 58.42% | ↗ |
| 7 | 2023 | John Fair Former Chief Commercial Officer | 386.0K | — | — | 278.8K | 77.2K | 13.2K | 755.2K | 36.92% | ↗ |
| 8 | 2023 | Lisa Walters-Hoffert Former Chief Financial Officer | 380.0K | — | — | 278.8K | 76.0K | 13.2K | 748.0K | 37.27% | ↗ |
| 9 | 2023 | MarDee Haring-Layton Chief Accounting Officer | 295.0K | — | — | 79.8K | 44.3K | 13.2K | 432.3K | 18.46% | ↗ |
| 10 | 2022 | Sabrina Martucci Johnson President and Chief Executive Officer | 465.8K | — | — | 869.4K | 326.1K | 12.2K | 1.67M | 51.95% | ↗ |
| 11 | 2022 | Lisa Walters-Hoffert Chief Financial Officer | 365.0K | — | — | 256.2K | 146.0K | 12.2K | 779.4K | 32.87% | ↗ |
| 12 | 2022 | Lisa Walters-Hoffert Former Chief Financial Officer | 365.0K | — | — | 256.2K | 146.0K | 12.2K | 779.4K | 32.87% | ↗ |
| 13 | 2022 | John Fair Former Chief Commercial Officer | 365.0K | — | — | 256.2K | 146.0K | 8.4K | 775.6K | 33.04% | ↗ |
| 14 | 2022 | John Fair Chief Commercial Officer | 365.0K | — | — | 256.2K | 146.0K | 8.4K | 775.6K | 33.04% | ↗ |
| 15 | 2021 | Sabrina Martucci Johnson President and Chief Executive Officer | 405.0K | — | — | 1.18M | 226.8K | 11.6K | 1.82M | 64.71% | ↗ |
| 16 | 2021 | Lisa Walters-Hoffert Chief Financial Officer | 324.0K | — | — | 377.5K | 103.7K | 11.6K | 816.9K | 46.22% | ↗ |
| 17 | 2021 | John Fair Chief Commercial Officer | 324.0K | — | — | 377.5K | 103.7K | 8.1K | 813.4K | 46.42% | ↗ |
| 18 | 2021 | John Fair Chief Strategy Officer | 324.0K | — | — | 377.5K | 103.7K | 8.1K | 813.4K | 46.42% | ↗ |
| 19 | 2020 | Sabrina Martucci Johnson President and Chief Executive Officer | 368.2K | — | — | 272.8K | 182.3K | 11.4K | 834.7K | 32.69% | ↗ |
| 20 | 2020 | Lisa Walters-Hoffert Chief Financial Officer | 294.6K | — | — | 66.3K | 92.8K | 11.4K | 465.0K | 14.25% | ↗ |
| 21 | 2020 | John Fair Chief Strategy Officer | 294.6K | — | — | 66.3K | 92.8K | 7.3K | 461.0K | 14.37% | ↗ |
| 22 | 2019 | Sabrina Martucci Johnson President and Chief Executive Officer | 334.8K | — | — | 140.5K | 142.3K | 11.2K | 628.8K | 22.35% | ↗ |
| 23 | 2019 | Lisa Walters-Hoffert Chief Financial Officer | 267.8K | — | — | 54.1K | 79.7K | 11.2K | 412.7K | 13.10% | ↗ |
| 24 | 2018 | Sabrina Martucci Johnson President and Chief Executive Officer | 325.0K | — | — | 185.0K | 97.5K | 10.7K | 618.2K | 29.92% | ↗ |
| 25 | 2018 | Lisa Walters-Hoffert Chief Financial Officer | 260.0K | — | — | 96.3K | 54.6K | 9.5K | 420.5K | 22.91% | ↗ |
| 26 | 2017 | Christopher D. T. Guiffre, J.D. Former Chief Executive Officer | 311.4K | 244.8K | — | 280.5K | — | 1.02M | 1.85M | 15.13% | ↗ |
| 27 | 2017 | Adrian Senderowicz, M.D. Former SVP & Chief Medical Officer | 209.5K | 204.2K | — | 177.7K | — | 115.6K | 743.0K | 23.91% | ↗ |
| 28 | 2017 | Scott Eliasof, Ph.D. Former SVP & Chief Scientific Officer | 169.7K | 160.0K | — | 135.4K | — | 100.0K | 565.1K | 23.95% | ↗ |
| 29 | 2017 | Sabrina Martucci Johnson President and Chief Executive Officer | 144.3K | — | — | — | 146.3K | — | 290.5K | 0.00% | ↗ |
| 30 | 2017 | Lisa Walters-Hoffert Chief Financial Officer | 115.1K | 45.5K | — | — | 36.4K | — | 197.0K | 0.00% | ↗ |
| 31 | 2016 | Christopher D. T. Guiffre, J.D. Former Chief Executive Officer | 480.0K | 240.0K | — | 237.5K | — | 11.2K | 968.8K | 24.52% | ↗ |
| 32 | 2016 | Adrian Senderowicz, M.D. Former SVP & Chief Medical Officer | 400.5K | 160.2K | — | 154.6K | — | 11.6K | 726.9K | 21.27% | ↗ |
| 33 | 2016 | Scott Eliasof, Ph.D. Former SVP & Chief Scientific Officer | 297.5K | 95.1K | — | 130.7K | — | 12.4K | 534.7K | 24.45% | ↗ |
| 34 | 2015 | Christopher D.T. Guiffre President and Chief Executive Officer | 420.2K | 221.9K | — | 2.63M | — | 11.2K | 3.28M | 80.09% | ↗ |
| 35 | 2015 | Adrian M. Senderowicz, M.D. Senior Vice President and Chief Medical Officer | 125.6K | 158.3K | — | 865.8K | — | 293.8K | 1.44M | 59.98% | ↗ |
| 36 | 2015 | Alejandra V. Carvajal, J.D. Vice President, General Counsel | 280.0K | 81.2K | — | 497.0K | — | 11.2K | 869.4K | 57.17% | ↗ |
| 37 | 2014 | Oliver S. Fetzer, Ph.D. Former President and Chief Executive Officer | 324.4K | — | — | 1.09M | — | 14.8K | 1.43M | 76.34% | ↗ |
| 38 | 2014 | Christopher D.T. Guiffre President and Chief Executive Officer | 317.1K | 115.5K | — | 387.3K | — | 11.2K | 831.1K | 46.60% | ↗ |
| 39 | 2014 | Christopher D.T. Guiffre, J.D. President and Chief Executive Officer | 317.1K | 115.5K | — | 387.3K | — | 11.2K | 831.1K | 46.60% | ↗ |
| 40 | 2014 | Edward G. Garmey, M.D. Chief Medical Officer and Senior Vice President | 309.0K | 98.9K | — | 243.4K | — | 11.2K | 662.4K | 36.74% | ↗ |
| 41 | 2014 | Karen L. Roberts Senior Vice President, Finance and Administration | 242.0K | 59.9K | — | 260.8K | — | 11.2K | 573.8K | 45.44% | ↗ |
| 42 | 2014 | Alejandra V. Carvajal, J.D. Vice President, General Counsel | 76.5K | 113.5K | — | 137.0K | — | 2.1K | 329.0K | 41.63% | ↗ |
| 43 | 2013 | Oliver S. Fetzer, Ph.D. Former President and Chief Executive Officer | 352.0K | 176.0K | — | 146.1K | — | 11.0K | 685.1K | 21.32% | ↗ |
| 44 | 2013 | Edward G. Garmey, M.D. Chief Medical Officer and Senior Vice President | 303.0K | 75.8K | — | — | — | 11.0K | 389.7K | 0.00% | ↗ |
| 45 | 2013 | Christopher D.T. Guiffre, J.D. President and Chief Executive Officer | 295.0K | 73.8K | — | — | — | 11.0K | 379.7K | 0.00% | ↗ |
| 46 | 2013 | Karen L. Roberts Senior Vice President, Finance and Administration | 230.0K | 57.5K | — | — | — | 11.0K | 298.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sabrina Martucci Johnson | Chief Executive Officer, President, Principal Financial Officer, Secretary & Director | 532.7K | female |
| MarDee J. Haring-Layton | Chief Accounting Officer | 367.1K | female |
| David Friend | Chief Scientific Officer | — | — |
| Jennifer Kiang | Vice President of Corporate Affairs & Development | — | — |
| Mark Walters | Vice President of Operations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DARE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
